3 ms·

>Are there clinical trials which mix and match vaccines, e.g. as boosters? Why do clinical trials when you can do live trials for free. Just wait a few month a

>Are there clinical trials which mix and match vaccines, e.g. as boosters? Why do clinical trials when you can do live trials for free. Just wait a few month and look at the situation in France. France bought a huge stock of Moderna but people there only want Pfizer, so now they have a huge stock of Moderna and a shortage of Pfizer. So to re-balance their inventory they decided that people over 30 can no longer have the choice of what vaccine they get. And they have also recently speed-up vaccination effort by requiring to have a less than 7 month injection/contamination after January the 15th or be severely constrained in daily life. So in about two months, you'll have a huge influx of guinea pigs data. So if you just turned 30 and never vaccinated you are up for the Moderna huge dose that they tell you they consider not safe for people a few days younger than you are, (and the dosage was probably too heavy because it has now been reduced for the boosters).

walterbell 5y ago
Thanks for the field report. Wish we could organize a open-source data collection exercise for live trials and input parameters with regional/policy path dependence. That could enable retroactive analysis across inadvertent cohorts.
dablweb 5y ago
It's astonishing that the majority of people can look at this situation and not recoil. The whole "mix and match" narrative is just so misguided. I do wonder if it's being pushed as a way to dilute possible lawsuits.
- walterbell 5y ago
  Random choices, permutations and timing of vendors will make it difficult to determine cause and effect. No control groups. If there are future adverse events, they may be attributed to a specific human rather than a cohort of peers. This could justify more observational surveillance and testing, laying the groundwork for future personalized treatments, including unique vaccines. In that hypothetical scenario, rare injuries could lead to more live trials on those humans.
- deleted 5y ago
  [deleted]

walterbell 5y ago

Thanks for the field report. Wish we could organize a open-source data collection exercise for live trials and input parameters with regional/policy path dependence. That could enable retroactive analysis across inadvertent cohorts.

dablweb 5y ago

It's astonishing that the majority of people can look at this situation and not recoil. The whole "mix and match" narrative is just so misguided. I do wonder if it's being pushed as a way to dilute possible lawsuits.

walterbell 5y ago
Random choices, permutations and timing of vendors will make it difficult to determine cause and effect. No control groups. If there are future adverse events, they may be attributed to a specific human rather than a cohort of peers. This could justify more observational surveillance and testing, laying the groundwork for future personalized treatments, including unique vaccines. In that hypothetical scenario, rare injuries could lead to more live trials on those humans.
deleted 5y ago
[deleted]